help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

The Oncologist, Vol. 12, No. 5, 610-621, May 2007; doi:10.1634/theoncologist.12-5-610
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lynch, T. J.
Right arrow Articles by Lacouture, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lynch, T. J., Jr.
Right arrow Articles by Lacouture, M. E.

Symptom Management and Supportive Care

Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management

Thomas J. Lynch, Jr.a, Ed S. Kimb, Beth Eabyc, Jody Gareyb, Dennis P. Westd, Mario E. Lacoutured

aMassachusetts General Hospital, Boston, Massachusetts, USA; bMD Anderson Cancer Center, Houston, Texas, USA; cUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA; dNorthwestern University, Chicago, Illinois, USA

Key Words. EGFR • Erlotinib • Cetuximab • Panitumumab • Cutaneous toxicity • Pathobiology Forum Consensus

Correspondence: Thomas J. Lynch, Jr., M.D., Massachusetts General Hospital, 55 Fruit Street, YAW7, Boston, Massachusetts 02114, USA. Telephone: 617-726-2408; Fax: 617-724-1137; e-mail: tlynch{at}partners.org

Epidermal growth factor receptor inhibitors (EGFRIs) have demonstrated improved overall survival in patients with non-small cell lung cancer, pancreatic cancer, and colorectal cancer; however, their use is associated with dermatologic reactions of varying severity. The similar spectrum of events observed with monoclonal antibodies and tyrosine kinase inhibitors suggests such toxicities are a class effect. While such reactions do not necessarily require any alteration in EGFRI treatment, being best addressed through symptomatic treatment, there is limited evidence on which to base such therapies. In October 2006, at an international and interdisciplinary EGFRI dermatologic toxicity forum, the underlying mechanisms of these toxicities were discussed and commonly used therapeutic interventions were evaluated. Our aim was to reach a current consensus on management strategies. A three-tiered, EGFRI-focused toxicity grading system is suggested for the purposes of therapeutic decision making, and as a framework on which to build a stepwise approach to intervention. This approach to successful management is specifically tailored to accurately categorize dermatologic toxicity associated with EGFRIs, and can be easily applied by all health care professionals. The goal is to maximize quality of life in patients who are being treated with these agents—many of whom will be on these drugs for several months or even years.

Disclosure of potential conflicts of interest is found at the end of this article.




This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
J. Schwartz
Current combination chemotherapy regimens for metastatic breast cancer
Am. J. Health Syst. Pharm., December 1, 2009; 66(23_Supplement_6): S3 - S8.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
E. H. Tan and A. Chan
Evidence-Based Treatment Options for the Management of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors
Ann. Pharmacother., October 1, 2009; 43(10): 1658 - 1666.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
H. Piessevaux, M. Buyse, W. De Roock, H. Prenen, M. Schlichting, E. Van Cutsem, and S. Tejpar
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
Ann. Onc., August 1, 2009; 20(8): 1375 - 1382.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
N. Thatcher, M. Nicolson, R. W. Groves, J. Steele, B. Eaby, J. Dunlop, J. McPhelim, R. Nijjar, I. Ukachukwu, and U.K. Erlotinib Skin Toxicity Management Consensus
Expert Consensus on the Management of Erlotinib-Associated Cutaneous Toxicity in the U.K.
Oncologist, August 1, 2009; 14(8): 840 - 847.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
C.-H. Kohne and H.-J. Lenz
Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
Oncologist, May 1, 2009; 14(5): 478 - 488.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J. A. Wolfram, D. Diaconu, D. A. Hatala, J. Rastegar, D. A. Knutsen, A. Lowther, D. Askew, A. C. Gilliam, T. S. McCormick, and N. L. Ward
Keratinocyte but Not Endothelial Cell-Specific Overexpression of Tie2 Leads to the Development of Psoriasis
Am. J. Pathol., April 1, 2009; 174(4): 1443 - 1458.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
N. A. Pennell and T. J. Lynch Jr.
Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
Oncologist, April 1, 2009; 14(4): 399 - 411.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
R. S. Herbst and A. Sandler
Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
Oncologist, November 1, 2008; 13(11): 1166 - 1176.
[Abstract] [Full Text] [PDF]


Home page
Arch DermatolHome page
R. G. Pomerantz, R. E. Chirinos, L. D. Falo Jr, and L. J. Geskin
Acitretin for Treatment of EGFR Inhibitor-Induced Cutaneous Toxic Effects
Arch Dermatol, July 1, 2008; 144(7): 949 - 950.
[Full Text] [PDF]


Home page
The OncologistHome page
H. Burris III and C. Rocha-Lima
New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways
Oncologist, March 1, 2008; 13(3): 289 - 298.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
C. Widakowich, G. de Castro Jr., E. de Azambuja, P. Dinh, and A. Awada
Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Oncologist, December 1, 2007; 12(12): 1443 - 1455.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.